2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2764

Head-to-Head Comparison of the Retention Rate of First Biologics in Elderly Patients with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Abstract Number: 2765

Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Abstract Number: 2766

Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries
Abstract Number: 2767

Comparative Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated By Serum Amyloid a
Abstract Number: 2768

Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Abstract Number: 2769

Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Abstract Number: 2770

Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study
Abstract Number: 2771

Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Abstract Number: 2772

Activated Memory B Cells in Rheumatoid Arthritis and Relationship to Anti-TNF Treatment
Abstract Number: 2773

Novel Mechanisms of Action for Methotrexate and Doxycycline: Prevention of Protein Adduct Formation and Free Radical Scavenging
Abstract Number: 2774

Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Abstract Number: 2775

What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?
Abstract Number: 2776

Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection
Abstract Number: 2777

Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan
Abstract Number: 2778

Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].